Single-cell RNA sequencing (scRNA-seq) technologies are poised to reshape the current cell-type classification system. However, a transcriptome-based single-cell atlas has not been achieved for complex mammalian systems. Here, we developed Microwell-seq, a high-throughput and low-cost scRNA-seq platform using simple, inexpensive devices. Using Microwell-seq, we analyzed more than 400,000 single cells covering all of the major mouse organs and constructed a basic scheme for a mouse cell atlas (MCA). We reveal a single-cell hierarchy for many tissues that have not been well characterized previously. We built a web-based "single-cell MCA analysis" pipeline that accurately defines cell types based on single-cell digital expression. Our study demonstrates the wide applicability of the Microwell-seq technology and MCA resource.

It has come to our attention that in preparing the final version of this paper, we inadvertently misspelled the first name of an author Ziming Zhou as ''Zimin Zhou''. In addition, we have made two errors in describing the reagents in the STAR Methods. First, under the subheading of ''Synthesis of barcoded beads'' in the Method Details section, the supplier of the magnetic beads coated with carboxyl groups should be Suzhou Knowledge & Benefit Sphere Tech. Co., Ltd. (diameter 20-25 mm, http://www.kbspheretech. com/), instead of Zhiyi. Second, under the subheading of ''Cell collection and lysis'' in the Method Details section, the concentration of Tris-HCL for the cold lysis buffer should be 0.1 M, instead of 1 M. These errors have been corrected online, and we apologize for any confusions we may have caused.

No abstract

A Sb/C nanocomposite was synthesized and found to deliver a reversible 3 Na storage capacity of 610 mA h g(-1), a strong rate capability at a very high current of 2000 mA g(-1) and a long-term cycling stability with 94% capacity retention over 100 cycles, offering practical feasibility as a high capacity and cycling-stable anode for room temperature Na-ion batteries.

Key Points• There is a need to identify the best HLA haplotypemismatched related donor.• Use of young, male, NIMAmismatched donors results in the best survival after HLA haplotype-mismatched related donor transplants. Older sister donors were inferior to father donors with regard to NRM (HR 5 1.87; 95% CI 5 1.10-3.20; P 5 .02) and survival (HR 5 1.59; 95% CI 5 1.05-2.40; P 5 .03). Noninherited maternal antigen-mismatched sibling donors were associated with the lowest incidence of acute GVHD compared with parental donors and noninherited paternal antigen-mismatched sibling donors. Specific HLA disparities were not significantly correlated with transplant outcomes. Our data indicate which HLA haplotypemismatched related donors are associated with the best transplant outcomes in persons with hematological neoplasms. (Blood. 2014; 124(6):843-850)

No abstract

No abstract

No abstract